Following an oversubscribed first closing in February, HEMEX, a bench-to-market clinical Contract Research Organisation (CRO) and early-stage healthcare investment firm, has held the second closing of it Series C fundraising round at CHF7.1 million.
All existing “Investor Club” members followed-up in this round and are joined by new investors.
Since 2015, HEMEX has been offering life science consulting services from its headquarters in Liestal, Switzerland. In 2017, the company opened a subsidiary in Germany, and in 2018, the USA followed. As of 2019, the company has signed a partnership agreement with China’s Henan province and is planning to continue its global expansion.
HEMEX offers healthcare startups all the services needed to bring lead products to the market in the EU and the US, especially during the clinical development phase (clinical trials, regulatory affairs, quality assurance). HEMEX’ team has strong expertise in clinical development of innovative pharmaceuticals, medical devices, in vitro diagnostics, and digital health applications, both for human and animal health.
Pascal Winnen, co-founder, board member and CEO, says: “We are extremely pleased to have closed our Series C round in such a short time. The continued support of our existing investors, as well as several strong investors joining, shows the potential of our business model. With our fast-growing team of highly qualified healthcare professionals as well as a strong network of specialised consultants, we will continue to offer our shareholders the opportunity to identify and invest in early-stage healthcare startups, with active management of the portfolio.”
Besides consulting, HEMEX also supports startups financially through investments in early-stage funding rounds. As a renowned Swiss “smart money” healthcare investor, HEMEX often takes the lead in due diligence, structuring the round with its co-investors, and subsequent active management of its investment. Our investment strategy not only provides executive leadership support, but also supports our portfolio companies as a CRO to assist in the business development and the generation of high-quality, robust clinical data in a heavily regulated environment, that ultimately leads to market approval and a successful exit.
